DFFN
Diffusion Pharmaceuticals Inc
Price:  
4.40 
USD
Volume:  
351,057.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

DFFN WACC - Weighted Average Cost of Capital

The WACC of Diffusion Pharmaceuticals Inc (DFFN) is 8.8%.

The Cost of Equity of Diffusion Pharmaceuticals Inc (DFFN) is 12.70%.
The Cost of Debt of Diffusion Pharmaceuticals Inc (DFFN) is 5.00%.

Range Selected
Cost of equity 9.40% - 16.00% 12.70%
Tax rate 1.40% - 3.60% 2.50%
Cost of debt 5.00% - 5.00% 5.00%
WACC 7.2% - 10.4% 8.8%
WACC

DFFN WACC calculation

Category Low High
Long-term bond rate 4.2% 4.7%
Equity market risk premium 5.0% 6.0%
Adjusted beta 1.05 1.81
Additional risk adjustments 0.0% 0.5%
Cost of equity 9.40% 16.00%
Tax rate 1.40% 3.60%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 7.2% 10.4%
Selected WACC 8.8%

DFFN's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for DFFN:

cost_of_equity (12.70%) = risk_free_rate (4.45%) + equity_risk_premium (5.50%) * adjusted_beta (1.05) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.